Author

admin

Browsing

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), today announced that it has completed its trial entitled “A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants.” A final safety review committee…

NVIDIA’s (NASDAQ:NVDA) results have once again exceeded analysts’ expectations. Despite bearish sentiment leading up to the release of its earnings, the company delivered strong results for its fourth fiscal quarter of 2025, driven by the surging demand for its artificial intelligence (AI) solutions. Quarterly revenue reached US$39.3 billion, a 78…